Replies to post #26728 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 4Q22 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency)   
 Medical devices*  37%        +7% 
 Diagnostics       33%       -21% 
 Nutrition         18%        -6% 
 Drugs†            12%       +11%

4Q22 COVID-diagnostics sales were $1.07B (32% of total 4Q22 diagnostic sales), down from $1.70B in 3Q22.

58% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.